Cancer and ageing
Human evidence and active trials are visible in this field
515 human-evidence records · 160 active trials · 560 visible funding records · 6,594 universities
Australian Patent Application
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
Source-linked patent metadata for Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2018357829
- Earliest priority
- December 30, 2017
- Application date
- May 2, 2019
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Senolytics
Human evidence and active trials are visible in this field
198 human-evidence records · 12 active trials · 872 visible funding records · 7,604 universities
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Cancer and ageing82% metadata match
Senolytics82% metadata match
How the patent office classifies this invention
A61K31/00 · C07K5/00
Verify in the original patent source →